Jennifer Niemi
Family · Spokane, WANPI 1598054249
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 95.0% of the total across 228 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 24.2% of the total. Among family clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $23.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$822
- United Therapeutics Corporation$774
- Sanofi$348
- Electromed, Inc.$227
- Actelion Pharmaceuticals US, Inc.$219
- plus $2K from 17 others
What the payments were for
- Food & beverage$5,15695%
- Education$2705%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 43 | $1,315 |
| GSK | 81 | $822 |
| United Therapeutics Corporation | 18 | $774 |
| Sanofi | 18 | $348 |
| Electromed, Inc. | 5 | $227 |
| Actelion Pharmaceuticals US, Inc. | 5 | $219 |
| Boehringer Ingelheim | 7 | $218 |
| Inari Medical, Inc. | 1 | $217 |
| Baxter Healthcare | 9 | $193 |
| Merck | 6 | $170 |
| Regeneron Healthcare Solutions, Inc. | 5 | $151 |
| Insmed, Inc. | 4 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $97 |
| Verona Pharma, Inc. | 4 | $89 |
| Amgen | 4 | $73 |
| Vifor Pharma, Inc. | 4 | $73 |
| Mylan Specialty L.p. | 3 | $71 |
| Pfizer | 1 | $62 |
| Grifols USA, LLC | 3 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $55 |
| Philips North America LLC | 2 | $36 |
| Viatris Specialty LLC | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$619
- FASENRA$380
- AIRSUPRA$380
- BREZTRI$255
- FLOWTRIEVER CATHETER, S$217
- CT THROMBECTOMY SYSTEM KIT$217
- REMODULIN$119
- SYMBICORT$116
How this compares
$5,426 in reported general payments places this provider in the 95th percentile of 1,706 family providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 272 | $228,136 |
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $179,181 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 184 | $141,636 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 167 | $104,572 |
| Spiriva RespimatTiotropium Bromide | 116 | $80,833 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 137 | $72,407 |
| Dupixent PenDupilumab | 17 | $71,665 |
| SymbicortBudesonide/Formoterol Fumarate | 101 | $34,069 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $27,567 |
| Spiriva HandihalerTiotropium Bromide | 33 | $23,902 |
| DuleraMometasone/Formoterol | 46 | $20,714 |
| Advair HfaFluticasone Propion/Salmeterol | 36 | $19,778 |
| Incruse ElliptaUmeclidinium Bromide | 24 | $11,788 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 77 | $10,553 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 333 | $10,067 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta | $822 | $343,371495 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat, Combivent Respimat | $218 | $192,127297 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,315 | $175,705285 claims |
| MerckDulera | $170 | $20,71446 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,706 family providers in Washington.
Other family in Spokane
- Zelda SwainSpokane$83K
- Cheryl SomersSpokane$31K
- Lance VarnsSpokane$11K
- Jennifer BanksSpokane$9K
- Ruth MolletSpokane$6K
- Robert BaylessSpokane$6K
- Melissa TuftsSpokane$5K
- Rachel GalazkaSpokane$5K
- Sharla PetersonKenmore$192K
- Savannah MorganRenton$76K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.